Molecular diagnostics company MDNA Life Sciences has selected Phi Life Sciences to distribute its Prostate Mitomic Test, a proprietary liquid biopsy test for prostate cancer. The new partnership will allow the two companies to offer their products in more than 100 countries and territories around the world.
Molecular diagnostics company MDNA Life Sciences has selected Phi Life Sciences to distribute its Prostate Mitomic Test, a proprietary liquid biopsy test for prostate cancer. The CEO of MDNA Life Sciences said the partnership will help build the product's user base more quickly and encourage market adoption.